Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients With Resistant Hypertension and Chronic Kidney Disease

NCT03071263 is registered in ClinicalTrials.gov with Relypsa, Inc. as lead sponsor.

NCT NCT03071263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03071263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients With Resistant Hypertension and Chronic Kidney Disease
Lead sponsor
Relypsa, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 23, 2017
Completion date
November 27, 2018
Enrollment
295 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

hyperkalemia, resistant hypertension